Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene

Journal of Virology

Volumn 83, Issue 17, 2009, Pages 8849-8858

  Marcos Villar, Laura ^a,b   Lopitz Otsoa, Fernando ^c   Gallego, Pedro ^b   Muñoz Fontela, Cesar ^d   González Santamaría, José ^b   Campagna, Michela ^b   Shou Jiang, Gao ^e   Rodriguez, Manuel S ^c   Rivas, Carmen ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATENCY ASSOCIATED NUCLEAR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 2; LYSINE; PROMYELOCYTIC LEUKEMIA PROTEIN; SUMO 2 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; BIRC5 PROTEIN, HUMAN; LATENCY-ASSOCIATED NUCLEAR ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; VIRUS ANTIGEN;

ARTICLE; CELL DISRUPTION; CELL PROLIFERATION; CELL VIABILITY; GENE; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IMMUNOFLUORESCENCE; NONHUMAN; ONCOGENE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SITE DIRECTED MUTAGENESIS; STAINING; SURVIVIN GENE; UBIQUITINATION; WESTERN BLOTTING; BIOSYNTHESIS; DRUG ANTAGONISM; GENE SILENCING; METABOLISM; METHODOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

ANTIGENS, VIRAL; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HERPESVIRUS 8, HUMAN; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 69249206864     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00339-09     Document Type: Article

References (56)

1. Adamson, A. L., and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
2. Ahn, J. H., and G. S. Hayward. 2000. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 274: 39-55.
3. Ambrosini, G., C. Adida, and D. C. Altieri. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3:917-921.
4. Aoki, Y., G. M. Feldman, and G. Tosato. 2003. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101:1535-1542. (Pubitemid 36182531)
5. Bernardi, R., and P. P. Pandolfi. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8:1006-1016.
6. Bernardi, R., A. Papa, and P. P. Pandolfi. 2008. Regulation of apoptosis by PML and the PML-NBs. Oncogene 27:6299-6312.
7. Boddy, M. N., K. Howe, L. D. Etkin, E. Solomon, and P. S. Freemont. 1996. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13:971-982.
8. Boutell, C., A. Orr, and R. D. Everett. 2003. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J. Virol. 77:8686-8694. (Pubitemid 36936079)
9. Carvalho, T., J. S. Seeler, K. Ohman, P. Jordan, U. Pettersson, G. Akusjarvi, M. Carmo-Fonseca, and A. Dejean. 1995. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131:45-56.
10. Chelbi-Alix, M. K., and H. de The. 1999. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18:935-941.
11. Cheng, J., X. Kang, S. Zhang, and E. T. Yeh. 2007. SUMO-specific protease 1 is essential for stabilization of HIF1α during hypoxia. Cell 131:584-595. (Pubitemid 350007694)
12. Daniel, M. T., M. Koken, O. Romagne, S. Barbey, A. Bazarbachi, M. Stadler, M. C. Guillemin, L. Degos, C. Chomienne, and H. de The. 1993. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82:1858-1867. (Pubitemid 23278777)
13. Desbois, C., R. Rousset, F. Bantignies, and P. Jalinot. 1996. Exclusion of Int.-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. Science 273:951-953. (Pubitemid 26275170)
14. Desterro, J. M., M. S. Rodriguez, and R. T. Hay. 1998. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell 2:233-239. (Pubitemid 128373648)
15. Doucas, V., A. M. Ishov, A. Romo, H. Juguilon, M. D. Weitzman, R. M. Evans, and G. G. Maul. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207. (Pubitemid 26044607)
16. Engelhardt, O. G., C. Boutell, A. Orr, E. Ullrich, O. Haller, and R. D. Everett. 2003. The homeodomain-interacting kinase PKM (HIPK-2) modi- fies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML. Exp. Cell Res. 283: 36-50.
17. Esteban, M., M. A. Garcia, E. Domingo-Gil, J. Arroyo, C. Nombela, and C. Rivas. 2003. The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. J. Gen. Virol. 84:1463-1470.
18. Everett, R. D. 2001. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20:7266-7273.
19. Everett, R. D., and M. K. Chelbi-Alix. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
20. Hecker, C. M., M. Rabiller, K. Haglund, P. Bayer, and I. Dikic. 2006. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 281:16117-16127.
21. Hodges, M., C. Tissot, K. Howe, D. Grimwade, and P. S. Freemont. 1998. Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am. J. Hum. Genet. 63:297-304.
22. Ishov, A. M., A. G. Sotnikov, D. Negorev, O. V. Vladimirova, N. Neff, T. Kamitani, E. T. Yeh, J. F. Strauss III, and G. G. Maul. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234.
23. Ito, T., K. Shiraki, K. Sugimoto, T. Yamanaka, K. Fujikawa, M. Ito, K. Takase, M. Moriyama, H. Kawano, M. Hayashida, T. Nakano, and A. Suzuki. 2000. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080-1085. (Pubitemid 30233232)
24. Joo, C. H., Y. C. Shin, M. Gack, L. Wu, D. Levy, and J. U. Jung. 2007. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J. Virol. 81:8282-8292.
25. Katano, H., K. Ogawa-Goto, H. Hasegawa, T. Kurata, and T. Sata. 2001. Human-herpesvirus-8-encoded K8 protein colocalizes with the promyelocytic leukemia protein (PML) bodies and recruits p53 to the PML bodies. Virology 286:446-455. (Pubitemid 32721820)
26. Katano, H., Y. Sato, H. Itoh, and T. Sata. 2001. Expression of human herpesvirus 8 (HHV-8)-encoded immediate early protein, open reading frame 50, in HHV-8-associated diseases. J. Hum. Virol. 4:96-102.
27. Katano, H., Y. Sato, T. Kurata, S. Mori, and T. Sata. 2000. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 269:335-344. (Pubitemid 30210906)
28. Korioth, F., G. G. Maul, B. Plachter, T. Stamminger, and J. Frey. 1996. The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Exp. Cell Res. 229:155-158.
29. Lallemand-Breitenbach, V., M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. Peres, J. Zhou, J. Zhu, B. Raught, and H. de The. 2008. Arsenic degrades PML or PML-RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10:547-555.
30. Lallemand-Breitenbach, V., J. Zhu, F. Puvion, M. Koken, N. Honore, A. Doubeikovsky, E. Duprez, P. P. Pandolfi, E. Puvion, P. Freemont, and H. de The. 2001. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193:1361-1371.
31. Lubyova, B., M. J. Kellum, A. J. Frisancho, and P. M. Pitha. 2004. Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. J. Biol. Chem. 279:7643-7654.
32. Lubyova, B., and P. M. Pitha. 2000. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J. Virol. 74:8194-8201. (Pubitemid 30641667)
33. Maul, G. G. 1998. Nuclear domain 10, the site of DNA virus transcription and replication. Bioessays 20:660-667. (Pubitemid 28422226)
34. Maul, G. G., D. Negorev, P. Bell, and A. M. Ishov. 2000. Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. J. Struct. Biol. 129:278-287.
35. Muller, S., and A. Dejean. 1999. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73:5137-5143. (Pubitemid 29246776)
36. Munoz-Fontela, C., M. Collado, E. Rodriguez, M. A. Garcia, A. Alvarez-Barrientos, J. Arroyo, C. Nombela, and C. Rivas. 2005. Identification of a nuclear export signal in the KSHV latent protein LANA2 mediating its export from the nucleus. Exp. Cell Res. 311:96-105.
37. Munoz-Fontela, C., L. Marcos-Villar, F. Hernandez, P. Gallego, E. Rodriguez, J. Arroyo, S. J. Gao, J. Avila, and C. Rivas. 2008. Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J. Virol. 82:1518-1525.
38. Munoz-Fontela, C., E. Rodriguez, C. Nombela, J. Arroyo, and C. Rivas. 2003. Characterization of the bipartite nuclear localization signal of protein LANA2 from Kaposi's sarcoma-associated herpesvirus. Biochem. J. 374: 545-550. (Pubitemid 37094115)
39. Prudden, J., S. Pebernard, G. Raffa, D. A. Slavin, J. J. Perry, J. A. Tainer, C. H. McGowan, and M. N. Boddy. 2007. SUMO-targeted ubiquitin ligases in genome stability. EMBO J. 26:4089-4101. (Pubitemid 47462097)
40. Quignon, F., F. De Bels, M. Koken, J. Feunteun, J. C. Ameisen, and H. de The. 1998. PML induces a novel caspase-independent death process. Nat. Genet. 20:259-265.
41. Regad, T., and M. K. Chelbi-Alix. 2001. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20:7274-7286. (Pubitemid 33105016)
42. Rivas, C., A. E. Thlick, C. Parravicini, P. S. Moore, and Y. Chang. 2001. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75:429-438.
43. Seo, T., J. Park, C. Lim, and J. Choe. 2004. Inhibition of nuclear factor κB activity by viral interferon regulatory factor 3 of Kaposi's sarcoma-associated herpesvirus. Oncogene 23:6146-6155. (Pubitemid 39178867)
44. Shen, T. H., H. K. Lin, P. P. Scaglioni, T. M. Yung, and P. P. Pandolfi. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell 24:331-339.
45. Song, J., L. K. Durrin, T. A. Wilkinson, T. G. Krontiris, and Y. Chen. 2004. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl. Acad. Sci. USA 101:14373-14378.
46. Sun, H., J. D. Leverson, and T. Hunter. 2007. Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26:4102-4112. (Pubitemid 47462098)
47. Szekely, L., C. Kiss, K. Mattsson, E. Kashuba, K. Pokrovskaja, A. Juhasz, P. Holmvall, and G. Klein. 1999. Human herpesvirus-8-encoded LNA-1 accumulates in heterochromatin-associated nuclear bodies. J. Gen. Virol. 80: 2889-2900.
48. Tatham, M. H., M. C. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley, E. G. Jaffray, J. J. Palvimo, and R. T. Hay. 2008. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10:538-546.
49. Uzunova, K., K. Gottsche, M. Miteva, S. R. Weisshaar, C. Glanemann, M. Schnellhardt, M. Niessen, H. Scheel, K. Hofmann, E. S. Johnson, G. J. Praefcke, and R. J. Dohmen. 2007. Ubiquitin-dependent proteolytic control of SUMO conjugates. J. Biol. Chem. 282:34167-34175.
50. Wang, Z. G., D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi, and P. P. Pandolfi. 1998. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:266-272.
51. Weisshaar, S. R., K. Keusekotten, A. Krause, C. Horst, H. M. Springer, K. Gottsche, R. J. Dohmen, and G. J. Praefcke. 2008. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett. 582:3174-3178.
52. Wies, E., Y. Mori, A. Hahn, E. Kremmer, M. Sturzl, B. Fleckenstein, and F. Neipel. 2008. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 111:320-327.
53. Xie, Y., O. Kerscher, M. B. Kroetz, H. F. McConchie, P. Sung, and M. Hochstrasser. 2007. The yeast Hex3 · Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J. Biol. Chem. 282:34176-34184.
54. Xu, Z. X., R. X. Zhao, T. Ding, T. T. Tran, W. Zhang, P. P. Pandolfi, and K. S. Chang. 2004. Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. J. Biol. Chem. 279:1838-1844.
55. Zhao, J., T. Tenev, L. M. Martins, J. Downward, and N. R. Lemoine. 2000. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113:4363-4371. (Pubitemid 32000697)
56. Zhong, S., S. Muller, S. Ronchetti, P. S. Freemont, A. Dejean, and P. P. Pandolfi. 2000. Role of SUMO-1-modified PML in nuclear body formation. Blood 95:2748-2752. (Pubitemid 30235878)